For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > BUSINESS
BUSINESS
- Eisai Eyes Sales of 50 Billion Yen in Asian Generic Biz within 5 Years
March 15, 2013
- Shionogi, Kyoto University to Collaborate on Research for AD Treatment
March 15, 2013
- Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
- Astellas Files NDA in Japan for SGLT-2 Inhibitor Ipragliflozin
March 15, 2013
- API Corporation to Establish Production Base for Drug Substances, Intermediates in India
March 15, 2013
- Astellas Grants US Firm Global Rights to Ceftolozane
March 14, 2013
- Eli Lilly Japan’s 2012 Sales Surge 10% on Brisk Zyprexa; NHI Price Cut Countered
March 14, 2013
- Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
- A Number of Blockbuster Candidates Emerging from Japanese Pharmas’ In-house R&D: Dr Nakamura of Pharma Forum Institute
March 14, 2013
- Astellas, Ambit to Terminate Development Collaboration for FLT3 Kinase Inhibitors
March 14, 2013
- Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
- Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
- CSOs Diversifying Services in Japan amid Increasing Use of CMRs
March 12, 2013
- Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
- Kyowa Kirin to Start Constructing Manufacturing Plant in Gunma in May
March 12, 2013
- Hisamitsu to File for Chronic Pain for Fentos Tape in 2013
March 12, 2013
- Nihon Chouzai Obtains Loan from Development Bank of Japan to Strengthen Production Base for Generic Drugs
March 12, 2013
- Dolutegravir Shows Significant Superior Efficacy Compared to Raltegravir in PIII Study: Shionogi
March 12, 2013
- Qol Senior Managing Director Takada Proposes Utilization of CSO for Long-Listed Products and Generics
March 11, 2013
- Nippon Shinyaku Licenses OAB Drug from DSP, Aims for Launch of Nocturia Treatment in 2019
March 11, 2013
ページ
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…